Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11188MR)

This product GTTS-WQ11188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6384MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ6221MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ4327MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ6126MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ8649MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ6519MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ15688MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ520MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW